DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
DBV Technologies (Nasdaq: DBVT), a late-stage biopharmaceutical company, will participate in 1-on-1 investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, in Miami, FL.
CEO Daniel Tassé will not attend the previously scheduled fireside chat due to travel disruption.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – DBVT
On the day this news was published, DBVT gained 0.31%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 05 | Conference participation | Neutral | -0.9% | Announced CEO fireside chat and webcast for Goldman Sachs healthcare conference. |
| Jun 03 | Capital structure update | Neutral | -0.7% | Reported total shares and voting rights as of May 31, 2026. |
| Jun 03 | General meeting results | Positive | -0.7% | Shareholders approved all resolutions at the 2026 Combined General Meeting. |
| Jun 02 | Clinical trial milestone | Positive | -2.9% | First participant screened in THRIVE Phase 2 study of VIASKIN Peanut Patch. |
| May 13 | Meeting announcement | Neutral | +1.2% | Outlined agenda and logistics for Combined General Meeting on June 3, 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news, including governance and clinical updates, often coincided with modest negative price reactions, even when announcements were operationally positive or neutral.
Over the past month, DBV issued several updates, including conference participation announcements on Jun 5, 2026, governance and share-capital disclosures on Jun 3, 2026, and a clinical milestone on Jun 2, 2026 with the first participant screened in the THRIVE Phase 2 study. Shareholders also approved all resolutions at the 2026 Combined General Meeting. Despite generally constructive or neutral content, 24-hour price reactions ranged from -2.91% to +1.22%, indicating modest, mixed responses to news flow.
Regulatory & Risk Context
AI-generated analysis. How Rhea-AI works. Not financial advice.
Châtillon, France, June 9, 2026
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that company management will participate in 1-on-1 investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, in Miami, FL.
Mr. Daniel Tassé, CEO, will not be available for the previously scheduled fireside chat due to an unavoidable disruption of planned travel to the conference.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Relations Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
